Leuprolide (Leuprorelin)
Leuprolide is a synthetic 9-aa GnRH superagonist. Paradoxically, continuous use desensitizes GnRH receptors → profoundly suppresses LH, FSH, and sex steroids after 2-4 weeks. FDA-approved for prostate cancer, endometriosis, uterine fibroids, precocious puberty.
Community Rating
No ratings yet
Compound Profile
Leuprolide (Leuprorelin)
Key Data
Research reference only
Research Focus
Preclinical data
⚠ Research & Educational Use Only. Leuprolide (Leuprorelin) is a research chemical documented here for scientific education. All information references peer-reviewed literature and preclinical/clinical study data. Not for human consumption. Not medical advice. Consult a licensed researcher or healthcare professional before any laboratory use.
- Creates profound, reversible chemical castration — reduces testosterone to castrate levels (<50 ng/dL) within 2-4 weeks of continuous exposure
- FDA-approved for prostate cancer androgen deprivation therapy (standard of care for advanced disease)
- FDA-approved for endometriosis — hypoestrogenic state reduces ectopic endometrial lesions and pain
- Leuprolide (Leuprorelin) is not FDA-approved for human use. FDA-approved prescription drug (Lupron, AbbVie; generic leuprolide available). Schedule-III controlled substance in some jurisdictions. Prescription required.
Research At a Glance
- Creates profound, reversible chemical castration — reduces testosterone to castrate levels (<50 ng/dL) within 2-4 weeks of continuous exposure
- FDA-approved for prostate cancer androgen deprivation therapy (standard of care for advanced disease)
- FDA-approved for endometriosis — hypoestrogenic state reduces ectopic endometrial lesions and pain
- FDA-approved for uterine fibroids — shrinks fibroids pre-operatively
In Plain English
Simple summaryLeuprolide (leuprorelin) is a synthetic GnRH agonist that, when given as a depot injection once monthly or every 3-6 months, suppresses testosterone and estrogen to castrate levels within 2-4 weeks of starting treatment. It sounds paradoxical -- an agonist that suppresses -- but continuous GnRH receptor stimulation overwhelms and desensitizes GnRH receptors, eliminating pulsatile signaling that the reproductive axis requires. Lupron (leuprolide depot) has been FDA-approved since 1985 and is used for prostate cancer (androgen deprivation therapy), endometriosis, uterine fibroids, precocious puberty, and more recently as a gender-affirming puberty blocker. It's one of the most commercially successful peptide drugs in history.
- Creates profound, reversible chemical castration — reduces testosterone to castrate levels (<50 ng/dL) within 2-4 weeks of continuous exposure
- FDA-approved for prostate cancer androgen deprivation therapy
- FDA-approved for endometriosis — hypoestrogenic state reduces ectopic endometrial lesions and pain
The full scientific detail, mechanisms, citations, and dosing data, follows below.
What is Leuprolide (Leuprorelin)?
Tap any underlined term for an instant definition.
Leuprolide acetate (brand names: Lupron, Eligard, Viadur) is a synthetic nonapeptide (9-amino acid) superagonist analogue of gonadotropin-releasing hormone (GnRH, also called LHRH). It was developed by the Abbott Laboratories team in 1973 and received FDA approval in 1985 for prostate cancer.
The paradoxical pharmacology of leuprolide stems from the pulsatile nature of native GnRH signaling. Endogenous GnRH is released in pulses from the hypothalamus (every 60-120 minutes in males), and pulsatile GnRH stimulates pulsatile LH and FSH release from the pituitary. Continuous (non-pulsatile) GnRH exposure, however, leads to GnRH receptor downregulation and desensitization of the gonadotrophs.
**Mechanism:** 1. Days 1-14 (flare phase): Leuprolide activates GnRH receptors → initial LH/FSH surge → testosterone elevation (~2x baseline) → "testosterone flare." This can transiently worsen prostate cancer bone pain or cause neurological complications. 2. Days 14-28 (suppression phase): Persistent GnRH receptor stimulation → receptor internalization and downregulation → gonadotroph desensitization → LH and FSH collapse → testosterone falls to castrate levels (<50 ng/dL) 3. Maintenance: Castrate testosterone levels maintained for the duration of depot activity
**Depot formulation pharmacokinetics:** The 1-month, 3-month, 4-month, and 6-month depot formulations use poly-D,L-lactic-co-glycolic acid (PLGA) microspheres or polymer rods that slowly release leuprolide over time. The Viadur implant (12-month) and Eligard formulations differ in their polymer matrix composition.
**Reversibility:** Testosterone recovery after leuprolide discontinuation occurs in approximately: - 95% of patients within 12 months - Median time to recovery: 6-9 months (varies with age, duration of therapy)
Compared to surgical castration (orchiectomy), leuprolide ADT is reversible and psychologically preferable for most patients.
By the Numbers
Key Research Benefits
Documented effects observed in preclinical and clinical studies on Leuprolide (Leuprorelin). See all Hormonal Health peptides for comparison.
Side Effects & Risks
Adverse effects reported in the research literature. All data sourced from preclinical and clinical study reports. View all peptides' side effects →
Dosing Data from the Literature
Doses referenced below are sourced from published preclinical and clinical studies. Use the peptide dose calculator to convert these values to injection volume.
Leuprolide (Lupron) dosing by indication:
Prostate cancer: Lupron Depot 7.5 mg IM q28 days, 22.5 mg IM q3 months, or 45 mg IM q6 months Endometriosis: 3.75 mg IM monthly × 6 months (with norethindrone add-back to protect bone) Precocious puberty: 50 mcg/kg/day SC (pediatric) or depot formulations (7.5-15 mg IM monthly) Uterine fibroids: 3.75 mg IM monthly × 3-6 months pre-operatively
Initial antiandrogen (flutamide, bicalutamide): add for first 2 weeks to block testosterone flare in prostate cancer
Administration in Research Settings
Standard reconstitution and administration methodology for laboratory research use.
Depot formulations (microsphere or polymer suspensions) provide 1, 3, 4, or 6 month duration. IM injection into gluteal or deltoid muscle. Rotate sites. Aqueous solution (Lupron 5 mg/mL) for SC injection in daily dosing or pediatric precocious puberty.
What the research doesn't show
Long-term androgen deprivation with leuprolide causes significant side effects: osteoporosis, metabolic syndrome, cardiovascular risk, hot flashes, fatigue, and sexual dysfunction. These are real quality-of-life impacts that must be weighed against the cancer control benefits. Intermittent ADT (cycling on and off leuprolide) has been studied to reduce cumulative exposure, with mixed results on cancer control vs toxicity trade-off.
Medical Expert Videos
Physicians, researchers, and pharmacologists explain Leuprolide (Leuprorelin), covering mechanisms of action, clinical context, and study findings.
Videos sourced from YouTube search. KnowYourPeptide does not endorse any individual creator. For research education only.
The Bottom Line
Leuprolide (Leuprorelin) has a growing body of preclinical evidence and a well-characterised safety profile in research settings. The most-studied application is: creates profound, reversible chemical castration — reduces testosterone to castrate levels (<50 ng/dl) within 2-4 weeks of continuous exposure.
The most commonly reported side effect in research subjects is testosterone flare in first 1-2 weeks — may transiently worsen prostate cancer symptoms; prophylactic antiandrogen used. It is a research chemical, not approved for human use.
Frequently Asked Questions
Explore Further
Quick Reference
How It Compares
Triptorelin works through the same mechanism and is largely interchangeable with leuprolide for most indications. Degarelix is a GnRH antagonist that suppresses testosterone without the initial flare -- preferred when flare is dangerous (spinal cord metastases). Relugolix (Orgovyx) is an oral GnRH antagonist that achieves faster testosterone suppression and recovery -- increasingly preferred for its oral dosing and reversibility.
Compare Leuprolide (Leuprorelin) side-by-sideResearch Use Only
This information is for educational research purposes only. This is not medical advice. Consult a qualified healthcare professional.